Enteris BioPharma offers innovative formulation solutions built around its proprietary oral delivery technology platform – Peptelligence™. Since its founding in 2013, Enteris BioPharma has advanced multiple internal and external programs leveraging its Peptelligence™ platform. The technology has been developed and proven effective to enable the safe delivery of peptide-based therapeutics and other molecules with low oral bioavailability.

PEPTELLIGENCETM

Enteris BioPharma offers Intelligent Solutions for Oral Drug Delivery for BCS Class II, Class III and Class IV compounds, including peptides, in an enteric-coated tablet.

LEARN MORE

PIPELINE

Enteris BioPharma internal pipeline of products for women’s health are being evaluated and include Ovarest™ for endometriosis and Tobrate™ for uUTIs.

LEARN MORE

PARTNERING

Enteris BioPharma builds long-term relationships, with proven clinical stage biopharmaceutical oral peptide drug delivery solutions in novel formulations.

LEARN MORE

ABOUT US

Enteris BioPharma is a privately held, clinical stage biopharmaceutical company in NJ with formulation solutions via proprietary oral delivery technologies.

LEARN MORE

NEWS & EVENTS

Enteris, KeyBioscience to Develop Solutions for Metabolic Disorders Ferring, Enteris to Develop Oral Peptide Therapeutic

LEARN MORE
 
 

CONTACT US